Global Genetic Testing Market – North America is expected to account for higher market share of more than 55% driven by rising prevalence of genetic diseases in U.S. – Market Analysis and Forecast 2019 – 2026

Global Genetic Testing Market – North America is expected to account for higher market share of more than 55% driven by rising prevalence of genetic diseases in U.S. – Market Analysis and Forecast 2019 – 2026

Market Scenario

Global Genetic Testing Market is expected to grow at a CAGR of 14% to reach US$ XX  billion in 2026. Global Genetic Testing Market, By Technology The growth is coupled with the rising incidence of genetic disorders and reduction in the genetic testing prices. Around 6,00,920 cancer deaths occurred in the U.S. in 2017. Growing awareness among patients pertaining to the early diagnosis of diseases will lead to timely treatment resulting in reduced mortality. The rising incidence of diseases such as cancer, cystic fibrosis, Alzheimer’s and other genetic diseases worldwide will result in increasing number of people undergoing genetic testing for early diagnosis thereby fuelling the Global Genetic Testing Market growth. Other factors including Technological advancement in scientific research and research instrument is increasing the importance of genetic testing throughout the globe. Availability of sensitive and efficient DNA sequencing technique for parental genetic testing allows detection of the minute amount of DNA circulating in the mother’s blood during initial stages of pregnancy. Adoption of such non-invasive prenatal testing (NIPT) at a very early stage of pregnancy is increasing worldwide thereby augmenting the industry growth over the forecast period. In 2017, North America dominates the Global Genetic Testing Market. The Global Genetic Testing Market demand is coupled with an increased incidence of diseases by genetic disorders and high technological advancements. The U.S. dominated the genetic testing market in the North American region. The growth of U.S. is attributable to highly advanced infrastructure to support genetic testing, regulatory support for direct to consumer (DTC) genetic testing coupled with increasing insurance coverage and reduction in the cost of genetic tests. Asia-Pacific is expected to have a higher growth rate in the forecast period. The growth rate is driven by the major countries such as China and India. The factors including increasing R&D investment, a large pool of patients and rising government funding drive the market in the Asia-Pacific region. Other factors including advancements in genetic testing technologies, increasing prevalence of genetic diseases and growing awareness about early detection of diseases are also driving the Global Genetic Testing Market. Cancer is a major disease provide the highest Global Genetic Testing Market share of genetic testing in 2017. The cancer disease itself is one of the leading causes of mortality and morbidity globally and was responsible for 9.2 million deaths in 2016. Around 5%-10% of all the cancers are caused by inheriting the genetic mutation. The rising incidence of cancers is leading to a significant increase in the number of the genetic test conducted for testing cancer. The objective of the report is to present comprehensive Global Genetic Testing Market  including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Genetic Testing Market  North America for Asia Pacific dynamics, structure by analyzing the market segments, and project the Global Genetic Testing Market  North America for Asia Pacific   size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Genetic Testing Market  North America for Asia Pacific make the report investor’s guide.   Market Segmentation

• Global Genetic Testing Market, By Type

o Carrier Testing o Diagnostic Testing o Newborn Screening o Predictive and PR symptomatic Testing o Prenatal Testing o Nutrigenomic Testing Global Genetic Testing Market, By Disease o Alzheimer's Diseases o Cancer o Cystic Fibrosis o Sickle Cell Anemia o Duchenne Muscular Dystrophy o Thalassemia’s o Huntington's Disease o Special Diseases o Others Global Genetic Testing Market, By Technology o Cytogenetic Testing o Biochemical Testing o Molecular Testing The above data will be provided for following regions/countries from 2018-2026 (USD Million) • North America o U.S. o Canada • Europe o Germany o UK o France o Spain o Italy • Asia Pacific o China o India o Japan o Australia • Latin America o Argentina o Brazil o Mexico • Middle East and Africa o South Africa o Saudi Arabia What information is covered in a report? • Actual market numbers from 2013-2017, estimates and forecasts from 2019 to 2026 • Detailed market segmentation and market share analysis of each segment • Impact analysis of various drivers and trends • Market segmentation and landscape • Competitive landscape, 2017.

Table of Contents

Chapter 1 Research Methodology 1.1. Research Methodology 1.2. Market definition 1.3. Assumptions and Acronyms Used 1.4. Data Sources 1.4.1. Secondary 1.4.1.1. Paid 1.4.1.2. Unpaid 1.4.2. Primary Chapter 2 Executive Summary 2.1. Global Genetic Testing Market overview 2.1.1. By Type 2.1.2. By Technology 2.1.3. By Disease Chapter 3 Global Genetic Testing Market Industry Insights 3.1. Market segmentation and scope of study 3.2. Market Drivers and their impact analysis 3.2.1. Market Drivers 3.2.1.1. Genetic Discovery Creates New Diagnostic Markets 3.2.1.2. Point of Care Testing can increase demand 3.2.1.3. Fertility Practice 3.2.2. Market Restrains 3.2.2.1. Increased competition lowers price 3.3. Market share analysis 3.3.1. By Type 3.3.2. By Technology 3.3.3. By Disease 3.4. Competitive analysis 3.4.1. Key strategic initiatives 3.4.2. Regional presence 3.4.3. Product overview 3.5. Porter’s analysis 3.6. PESTEL analysis Chapter 4 Genetic Testing Market, By Type 4.1. Key segment trends 4.2. Carrier Testing 4.2.1. Market size, by region, 2019-2026 4.3. Diagnostic Testing 4.3.1. Market size, by region, 2019-2026 4.4. Newborn Screening 4.4.1. Market size, by region, 2019-2026 4.5. Predictive and PR symptomatic Testing 4.5.1. Market size, by region, 2019-2026 4.6. Prenatal Testing 4.6.1. Market size, by region, 2019-2026 4.7. Nutrigenomic Testing 4.7.1. Market size, by region, 2019-2026 4.7.2. Key Trends in Global Genetic Testing Market Chapter 5 Genetic Testing Market, By Disease 5.1. Key segment trends 5.2. Alzheimer's Diseases 5.2.1. Market size, by region, 2019-2026 5.3. Cancer 5.3.1. Market size, by region, 2019-2026 5.4. Cystic Fibrosis 5.4.1. Market size, by region, 2019-2026 5.5. Sickle Cell Anemia 5.5.1. Market size, by region, 2019-2026 5.6. Duchenne Muscular Dystrophy 5.6.1. Market size, by region, 2019-2026 5.7. Thalassemia’s 5.7.1. Market size, by region, 2019-2026 5.8. Huntington's Disease 5.8.1. Market size, by region, 2019-2026 5.9. Special Diseases 5.9.1. Market size, by region, 2019-2026 5.10. Others 5.10.1. Market size, by region, 2019-2026 Chapter 6 Genetic Testing Market, By Technology 6.1. Key segment trends 6.2. Cytogenetic Testing 6.2.1. Market size, by region, 2019-2026 6.3. Biochemical Testing 6.3.1. Market size, by region, 2019-2026 6.4. Molecular Testing 6.4.1. Market size, by region, 2019-2026 Chapter 7 Genetic Testing Market, By Region 7.1. Key regional trends 7.2. North America 7.2.1. Market size, by country, 2019-2026 7.2.2. Market size, by technology, 2019-2026 7.2.3. Market size, by type, 2019-2026 7.2.4. Market size, by disease, 2019-2026 7.2.5. U.S. 7.2.5.1. Market size, by technology, 2019-2026 7.2.5.2. Market size, by type, 2019-2026 7.2.5.3. Market size, by disease, 2019-2026 7.2.6. Canada 7.2.6.1. Market size, by technology, 2019-2026 7.2.6.2. Market size, by type, 2019-2026 7.2.6.3. Market size, by disease, 2019-2026 7.3. Europe 7.3.1. Market size, by country, 2019-2026 7.3.2. Market size, by technology, 2019-2026 7.3.3. Market size, by type, 2019-2026 7.3.4. Market size, by disease, 2019-2026 7.3.5. Germany 7.3.5.1. Market size, by technology, 2019-2026 7.3.5.2. Market size, by type, 2019-2026 7.3.5.3. Market size, by disease, 2019-2026 7.3.6. UK 7.3.6.1. Market size, by technology, 2019-2026 7.3.6.2. Market size, by type, 2019-2026 7.3.6.3. Market size, by disease, 2019-2026 7.3.7. France 7.3.7.1. Market size, by technology, 2019-2026 7.3.7.2. Market size, by type, 2019-2026 7.3.7.3. Market size, by disease, 2019-2026 7.3.8. Spain 7.3.8.1. Market size, by technology, 2019-2026 7.3.8.2. Market size, by type, 2019-2026 7.3.8.3. Market size, by disease, 2019-2026 7.3.9. Italy 7.3.9.1. Market size, by technology, 2019-2026 7.3.9.2. Market size, by type, 2019-2026 7.3.9.3. Market size, by disease, 2019-2026 7.4. Asia Pacific 7.4.1. Market size, by country, 2019-2026 7.4.2. Market size, by technology, 2019-2026 7.4.3. Market size, by type, 2019-2026 7.4.4. Market size, by disease, 2019-2026 7.4.5. India 7.4.5.1. Market size, by technology, 2019-2026 7.4.5.2. Market size, by type, 2019-2026 7.4.5.3. Market size, by disease, 2019-2026 7.4.6. China 7.4.6.1. Market size, by technology, 2019-2026 7.4.6.2. Market size, by type, 2019-2026 7.4.6.3. Market size, by disease, 2019-2026 7.4.7. Japan 7.4.7.1. Market size, by technology, 2019-2026 7.4.7.2. Market size, by type, 2019-2026 7.4.7.3. Market size, by disease, 2019-2026 7.4.8. Australia 7.4.8.1. Market size, by technology, 2019-2026 7.4.8.2. Market size, by type, 2019-2026 7.4.8.3. Market size, by disease, 2019-2026 7.5. Latin America 7.5.1. Market size, by country, 2019-2026 7.5.2. Market size, by technology, 2019-2026 7.5.3. Market size, by type, 2019-2026 7.5.4. Market size, by disease, 2019-2026 7.5.5. Argentina 7.5.5.1. Market size, by technology, 2019-2026 7.5.5.2. Market size, by type, 2019-2026 7.5.5.3. Market size, by disease, 2019-2026 7.5.6. Brazil 7.5.6.1. Market size, by technology, 2019-2026 7.5.6.2. Market size, by type, 2019-2026 7.5.6.3. Market size, by disease, 2019-2026 7.5.7. Mexico 7.5.7.1. Market size, by technology, 2019-2026 7.5.7.2. Market size, by type, 2019-2026 7.5.7.3. Market size, by disease, 2019-2026 7.6. Middle East and Africa 7.6.1. Market size, by country, 2019-2026 7.6.2. Market size, by technology, 2019-2026 7.6.3. Market size, by type, 2019-2026 7.6.4. Market size, by disease, 2019-2026 7.6.5. South Africa 7.6.5.1. Market size, by technology, 2019-2026 7.6.5.2. Market size, by type, 2019-2026 7.6.5.3. Market size, by disease, 2019-2026 7.6.6. Saudi Arabia 7.6.6.1. Market size, by technology, 2019-2026 7.6.6.2. Market size, by type, 2019-2026 7.6.6.3. Market size, by disease, 2019-2026 Chapter 8 Consolidations 8.1. Mergers and Acquisitions 8.2. Partnership, Joint Ventures and Strategic Alliances/Sales Agreements 8.3. Patent Analysis 8.4. Key players 8.4.1. Abbott Laboratories 8.4.1.1. Company overview 8.4.1.2. Key financials 8.4.1.3. Product landscape 8.4.1.4. Strategic initiatives 8.4.1.5. SWOT analysis 8.4.2. Roche Diagnostics 8.4.2.1. Company overview 8.4.2.2. Key financials 8.4.2.3. Product landscape 8.4.2.4. Strategic initiatives 8.4.2.5. SWOT analysis 8.4.3. Myriad Genetics, Inc. 8.4.3.1. Company overview 8.4.3.2. Key financials 8.4.3.3. Product landscape 8.4.3.4. Strategic initiatives 8.4.3.5. SWOT analysis 8.4.4. Thermo Fisher Scientific, Inc. 8.4.4.1. Company overview 8.4.4.2. Key financials 8.4.4.3. Product landscape 8.4.4.4. Strategic initiatives 8.4.4.5. SWOT analysis 8.4.5. Agilent Technologies, Inc. 8.4.5.1. Company overview 8.4.5.2. Key financials 8.4.5.3. Product landscape 8.4.5.4. Strategic initiatives 8.4.5.5. SWOT analysis 8.4.6. Hologic, Inc. 8.4.6.1. Company overview 8.4.6.2. Key financials 8.4.6.3. Product landscape 8.4.6.4. Strategic initiatives 8.4.6.5. SWOT analysis 8.4.7. Illumina, Inc. 8.4.7.1. Company overview 8.4.7.2. Key financials 8.4.7.3. Product landscape 8.4.7.4. Strategic initiatives 8.4.7.5. SWOT analysis 8.4.8. QIAGEN N.V. 8.4.8.1. Company overview 8.4.8.2. Key financials 8.4.8.3. Product landscape 8.4.8.4. Strategic initiatives 8.4.8.5. SWOT analysis 8.4.9. Cepheid 8.4.9.1. Company overview 8.4.9.2. Key financials 8.4.9.3. Product landscape 8.4.9.4. Strategic initiatives 8.4.9.5. SWOT analysis 8.4.10. Quest Diagnostics 8.4.10.1. Company overview 8.4.10.2. Key financials 8.4.10.3. Product landscape 8.4.10.4. Strategic initiatives 8.4.10.5. SWOT analysis 8.4.11. Precipio Inc. 8.4.11.1. Company overview 8.4.11.2. Key financials 8.4.11.3. Product landscape 8.4.11.4. Strategic initiatives 8.4.11.5. SWOT analysis 8.4.12. Ariosa Diagnositic Inc. 8.4.12.1. Company overview 8.4.12.2. Key financials 8.4.12.3. Product landscape 8.4.12.4. Strategic initiatives 8.4.12.5. SWOT analysis 8.4.13. Sequenom Inc. 8.4.13.1. Company overview 8.4.13.2. Key financials 8.4.13.3. Product landscape 8.4.13.4. Strategic initiatives 8.4.13.5. SWOT analysis 8.4.14. 23andMe 8.4.14.1. Company overview 8.4.14.2. Key financials 8.4.14.3. Product landscape 8.4.14.4. Strategic initiatives 8.4.14.5. SWOT analysis 8.4.15. Bayer Diagnostics 8.4.15.1. Company overview 8.4.15.2. Key financials 8.4.15.3. Product landscape 8.4.15.4. Strategic initiatives 8.4.15.5. SWOT analysis 8.4.16. Biocartis 8.4.16.1. Company overview 8.4.16.2. Key financials 8.4.16.3. Product landscape 8.4.16.4. Strategic initiatives 8.4.16.5. SWOT analysis 8.4.17. BioHelix 8.4.17.1. Company overview 8.4.17.2. Key financials 8.4.17.3. Product landscape 8.4.17.4. Strategic initiatives 8.4.17.5. SWOT analysis 8.4.18. BioMerieux 8.4.18.1. Company overview 8.4.18.2. Key financials 8.4.18.3. Product landscape 8.4.18.4. Strategic initiatives 8.4.18.5. SWOT analysis 8.4.19. BGI 8.4.19.1. Company overview 8.4.19.2. Key financials 8.4.19.3. Product landscape 8.4.19.4. Strategic initiatives 8.4.19.5. SWOT analysis 8.4.20. Counsyl 8.4.20.1. Company overview 8.4.20.2. Key financials 8.4.20.3. Product landscape 8.4.20.4. Strategic initiatives 8.4.20.5. SWOT analysis 8.4.21. deCODEme 8.4.21.1. Company overview 8.4.21.2. Key financials 8.4.21.3. Product landscape 8.4.21.4. Strategic initiatives 8.4.21.5. SWOT analysis 8.4.22. Genentech 8.4.22.1. Company overview 8.4.22.2. Key financials 8.4.22.3. Product landscape 8.4.22.4. Strategic initiatives 8.4.22.5. SWOT analysis 8.4.23. Genomictree 8.4.23.1. Company overview 8.4.23.2. Key financials 8.4.23.3. Product landscape 8.4.23.4. Strategic initiatives 8.4.23.5. SWOT analysis 8.4.24. IntegraGen 8.4.24.1. Company overview 8.4.24.2. Key financials 8.4.24.3. Product landscape 8.4.24.4. Strategic initiatives 8.4.24.5. SWOT analysis 8.4.25. LabCorp Diagnostic 8.4.25.1. Company overview 8.4.25.2. Key financials 8.4.25.3. Product landscape 8.4.25.4. Strategic initiatives

About This Report

Report ID10781
Category Healthcare
Published Dateoct 2019
No of Pages180
Contact Us
Call Now